Response to vaccination against hepatitis B in patients with Behcet's disease

Erkek, Emel; Ayaslioglu, Ergin; Erkek, Ayhan Bulent; Kurtipek, Gülcan Saylam; Bağci, Yeter

doi:10.1111/j.1440-1746.2005.03903.x

Cited by 27 publications

(16 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data on the efficacy of hepatitis B vaccination in AIIRD patients are lacking, but antibody concentrations are considered to correlate well with protection. Hepatitis B vaccination was immunogenic in most patients with AIIRD,153–156 although two open label small studies reported an insufficient humoral response to HBV vaccine in AIIRD patients treated with bDMARDs 157 158. Furthermore, high-dose HBV vaccination did not increase the humoral response rate 158…”

Section: Resultsmentioning

confidence: 99%

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

Furer

Rondaan

Heijstek

et al. 2020

Annals of the Rheumatic Diseases

615

531

View full text Add to dashboard Cite

To update the European League Against Rheumatism (EULAR) recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) published in 2011. Four systematic literature reviews were performed regarding the incidence/prevalence of vaccine-preventable infections among patients with AIIRD; efficacy, immunogenicity and safety of vaccines; effect of anti-rheumatic drugs on the response to vaccines; effect of vaccination of household of AIIRDs patients. Subsequently, recommendations were formulated based on the evidence and expert opinion. The updated recommendations comprise six overarching principles and nine recommendations. The former address the need for an annual vaccination status assessment, shared decision-making and timing of vaccination, favouring vaccination during quiescent disease, preferably prior to the initiation of immunosuppression. Non-live vaccines can be safely provided to AIIRD patients regardless of underlying therapy, whereas live-attenuated vaccines may be considered with caution. Influenza and pneumococcal vaccination should be strongly considered for the majority of patients with AIIRD. Tetanus toxoid and human papilloma virus vaccination should be provided to AIIRD patients as recommended for the general population. Hepatitis A, hepatitis B and herpes zoster vaccination should be administered to AIIRD patients at risk. Immunocompetent household members of patients with AIIRD should receive vaccines according to national guidelines, except for the oral poliomyelitis vaccine. Live-attenuated vaccines should be avoided during the first 6 months of life in newborns of mothers treated with biologics during the second half of pregnancy. These 2019 EULAR recommendations provide an up-to-date guidance on the management of vaccinations in patients with AIIRD.

show abstract

Section: Resultsmentioning

confidence: 99%

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

Furer

Rondaan

Heijstek

et al. 2020

Annals of the Rheumatic Diseases

615

531

View full text Add to dashboard Cite

show abstract

“…However, no comparative studies have been published so it is impossible to distinguish whether the immunosuppressive treatment, the disease activity of the AIIRD or the natural course of chronic hepatitis B infection was the cause of the hepatitis flare. Hepatitis B vaccination is efficacious in most patients with AIIRD 55–57. Vaccination for hepatitis A and/or B is only recommended when the risk of contracting these infections is increased (travel to or residence in endemic countries for hepatitis A and/or B); increased risk of exposure or proven exposure to hepatitis A and/or B (eg, because of medical profession, infected family member or contacts), only when protective antibodies against hepatitis A and/or B are absent.…”

Section: Resultsmentioning

confidence: 99%

EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

Assen

Agmon‐Levin

Elkayam

et al. 2011

Annals of the Rheumatic Diseases

548

408

View full text Add to dashboard Cite

Evidence was graded in categories I-IV, the strength of recommendations was graded in categories A-D and Delphi voting was applied to determine the level of agreement between the experts of the task force. Results Eight key questions and 13 recommendations addressing vaccination in patients with AIIRD were formulated. The strength of each recommendation was determined. Delphi voting revealed a very high level of agreement with the recommendations among the experts of the task force. Finally, a research agenda was proposed. Conclusion Recommendations for vaccination in patients with AIIRD based on the currently available evidence and expert opinion were formulated. More research is needed, particularly regarding the incidence of vaccine-preventable infectious diseases and the safety of vaccination in patients with AIIRD.

show abstract

“…120 In an uncontrolled study of HBV vaccination of 13 patients with Behçet disease, disease activity was not increased, with the exception of the development of oral aphthae in three patients. 121 Human papillomavirus vaccine A French case-control study including 211 patients with incident cases of autoimmune disease and 875 matched healthy individuals did not show an association between HPV vaccination (with Gardasil®, Merck, USA) and development of autoimmune disease. 146 Although anecdotal evidence exists of the incidence and relapse of SLE after HPV vaccination, 147,148 in a study that recruited 50 patients with SLE with low disease activity (median SLEDAI = 4), no increase in disease flares was observed after Gardasil® vaccination in comparison with 50 unvacci nated matched patients with SLE (0.22 versus 0.20 flares per patient per year).…”

Section: Hepatitis B Vaccinementioning

confidence: 99%

Vaccination of patients with autoimmune inflammatory rheumatic diseases

et al. 2014

View full text Add to dashboard Cite

Patients with autoimmune inflammatory rheumatic diseases (AIRDs) are at increased risk of infections. This risk has been further increased by the introduction of biologic agents over the past two decades. One of the most effective strategies to prevent infection is vaccination. However, patients with an AIRD have a compromised immune system, which is further impaired by medication. Another important issue is the possibility of triggering a broad nonspecific response by vaccination, potentially resulting in increased activity of the underlying autoimmune disease. In this Review, we provide an analysis of data on vaccination of patients with an AIRD. Both the efficacy and the safety of vaccination are addressed, together with the epidemiology of vaccine-preventable infectious diseases in different subgroups of adults with AIRDs. Special attention is given to vaccination of patients who are treated with biologic agents.

show abstract

Response to vaccination against hepatitis B in patients with Behcet's disease

Abstract: These preliminary findings might suggest that the majority of patients with Behcet's disease develop protective antibody response after hepatitis B vaccination and that the immune response against hepatitis B surface antigen is adequate, efficient and intact.

Cited by 27 publications

References 21 publications

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

Vaccination of patients with autoimmune inflammatory rheumatic diseases

Contact Info

Product

Resources

About